Trial site
Ascension Saint Francis Hospital-Milwaukee
Milwaukee, Wisconsin 53215, United StatesNot linked to an institution yet
The trials here
What the 14 trials at this site are about, from their registry records.
- Phase
- Phase 24 trials
- Phase 34 trials
- Phase 2/31 trial
- Status
- Active, not recruiting9 trials
- Recruiting5 trials
- Lead sponsor
- National Cancer Institute (NCI)8 trials
- Alliance for Clinical Trials in Oncology3 trials
- ECOG-ACRIN Cancer Research Group2 trials
- NRG Oncology1 trial
Running trials
Recruiting
Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays
NCT07283939· Alliance for Clinical Trials in Oncology· Source
Contact: Kamal Kant Singh Abbi (principal investigator)
Recruiting
Cost Communication and Financial Navigation in Cancer Patients (COSTCOM)
NCT06295367· ECOG-ACRIN Cancer Research Group· Source
Contact: Jonathan S. Treisman (principal investigator)
Recruiting
Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, ERASur Trial
NCT05673148· Phase 2· Alliance for Clinical Trials in Oncology· Source
Contact: Kamal Kant Singh Abbi (principal investigator)
Recruiting
Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps
NCT05080673· NRG Oncology· Source
Contact: Director, Department of Regulatory Affairs
Recruiting
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
NCT04566328· Phase 3· ECOG-ACRIN Cancer Research Group· Source
Contact: Jonathan S. Treisman (principal investigator)
Active, not recruiting
Study of Radiation Therapy Followed by Atezolizumab in Stage II or III Non-small Cell Lung Cancer Patients
NCT04310020· Phase 2· National Cancer Institute (NCI)· Source
Active, not recruiting
Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to the Usual Radiation Treatment for Newly Diagnosed Early Stage High Intermediate Risk Endometrial Cancer
NCT04214067· Phase 3· National Cancer Institute (NCI)· Source
Recruiting
Collection of Research Data and Samples From Patients Treated With Immunotherapy to Study Its Side Effects
NCT04242095· Alliance for Clinical Trials in Oncology· Source
Contact: Jonathan S. Treisman (principal investigator)
Active, not recruiting
De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer
NCT03952585· Phase 2/3· National Cancer Institute (NCI)· Source
Active, not recruiting
Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma
NCT03907488· Phase 3· National Cancer Institute (NCI)· Source
Active, not recruiting
A Study to Compare the Administration of Pembrolizumab After Surgery Versus Administration Both Before and After Surgery for High-Risk Melanoma
NCT03698019· Phase 2· National Cancer Institute (NCI)· Source
Active, not recruiting
Testing the Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia
NCT03737981· Phase 3· National Cancer Institute (NCI)· Source
Active, not recruiting
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
NCT02465060· Phase 2· National Cancer Institute (NCI)· Source
Active, not recruiting
Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
NCT02194738· National Cancer Institute (NCI)· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error